According to the population, Russian health care has coped with the increased load during the pandemic, the STADA Health Report has shown – the share of those satisfied with the state of this sphere in the Russian Federation has grown. Pharmaceutical market experts are not so complacent – as the statements made yesterday at the profile conference, the government failed to fully adapt the medical and pharmaceutical spheres to the new realities. Market participants, in particular, noted that the excessive regulation of the process of bringing innovative drugs to the market, as well as the lack of drug insurance in the country, deprive patients of many new effective drugs.
The pandemic did not lead to a crisis of Russians’ confidence in the national health care system, but the state was able to only partially adapt the medical and pharmaceutical spheres to the needs of patients. This conclusion can be drawn from the discussion held on Friday at the conference of the publishing house “Kommersant” “About pills and not only”.
According to the STADA Health Report presented at the event, 41% of Russians are satisfied with the work of the healthcare system and over the past year the share of satisfied people has increased by 7%. At the same time, in general, among the 15 countries of the world where the survey was conducted, this indicator, although it was initially higher than the Russian one (74%), decreased by 3 points.
It can be assumed that in Russia a certain contribution to the positive assessment was made by the liberalization of legislation in the pharmaceutical industry, which made it possible to provide infected patients with the necessary drugs. “In 2020, the government issued a number of regulations that made it easier to enter the market and circulation of a number of drugs needed in a pandemic, which indicates a certain flexibility,” said Teva, Director of Government Relations and Market Access at the conference. Andrey Kolesnikov. Viktoria Samsonova, head of the practice for work with companies in the healthcare and pharmaceutical sectors of KPMG in the CIS, disagreed with him: “The attempts at liberalization looked like an attempt to“ patch up the gaps ”the industry had been talking about for many years.”
According to Elena Litvinova, General Director of NovaMedica, for many companies, the excessive regulation of the process of bringing innovative drugs to the Russian market makes it unattractive and, as a result, Russian patients do not get access to the best treatment. “In recent years, about 900 new molecules have appeared on the world pharmaceutical market, more than half of them are still not represented in the Russian Federation,” she said. At the same time, Artur Valiev, General Director of Sun Pharma Russia, shared his observation that even if a pharmaceutical company registers a drug in the Russian Federation, it often may not supply it to the market due to the small number of potential consumers and the absence of a drug insurance system in the country.
According to the head of the Association of Pharmaceutical Companies Infarma, Vadim Kukava, such a mechanism for providing patients with drugs, according to the state plans for the development of the healthcare system, should have appeared several years ago: “However, it does not exist, and it is unclear whether it is planned to appear in the foreseeable future.” On the other hand, said Larisa Popovich, director of the Institute of Health Economics at the Higher School of Economics, although the drug insurance system in the Russian Federation is necessary, its introduction is fraught with certain difficulties and the delay of the authorities can be understood. According to her, a mechanism of end-to-end identification of each beneficiary is needed and it is necessary to clearly define the amount of state guarantees for each group of social beneficiaries in accordance with their diagnoses.